Insmed (INSM) Cash from Operations Growth (1y) (2011 - 2026)
Powered by 
Analysis
Insmed (INSM) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 75.53% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 332.04% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 4.87% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | -28.96% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | - |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 42.76% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 151.70% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 178.99% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | - |
| 10 | Insmed | 28.06 Bn | 26.90 Bn | 358.27 Mn | 56.79% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 56.79% |
| Mar 31, 2026 | 15.01% |
| Dec 31, 2025 | -26.34% |
| Sep 30, 2025 | -21.47% |
| Jun 30, 2025 | -67.19% |
| Mar 31, 2025 | -42.41% |
| Dec 31, 2024 | -49.81% |
| Sep 30, 2024 | -32.70% |
| Jun 30, 2024 | -0.13% |
| Mar 31, 2024 | -25.79% |
| Dec 31, 2023 | -26.83% |
| Sep 30, 2023 | -51.77% |
| Jun 30, 2023 | -20.03% |
| Mar 31, 2023 | -39.12% |
| Dec 31, 2022 | -22.60% |
| Sep 30, 2022 | -19.06% |
| Jun 30, 2022 | -35.60% |
| Mar 31, 2022 | 18.02% |
| Dec 31, 2021 | -25.96% |
| Sep 30, 2021 | -28.60% |